Monday, June 8, 2020

Avidity Biosciences Sets IPO Pricing Range

La Jolla-based Avidity Biosciences, which is developing oligonucleotide-based therapies for rare and serious diseases, has set the pricing range for its IPO, saying it is looking to sell 10 million shares at between $14.00 and $16.00 per share. The company said it has applied to list on the Nasdaq Global Market as RNA. Avidity Biosciences is venture backed by RTW Investments, Cormorant Asset Management, Eli Lilly and Company, ALETHEA Capital Management, and EcoR1 Capital.